Lanean...
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of <7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although...
Gorde:
Argitaratua izan da: | Gut |
---|---|
Egile Nagusiak: | , , , |
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
BMJ Publishing Group
2017
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256386/ https://ncbi.nlm.nih.gov/pubmed/27811314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-312539 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|